4,120 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Acquired by Van ECK Associates Corp

Van ECK Associates Corp bought a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,120 shares of the company’s stock, valued at approximately $40,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Harbor Capital Advisors Inc. grew its position in MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after acquiring an additional 770,744 shares in the last quarter. JPMorgan Chase & Co. grew its position in MiMedx Group by 265.4% in the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock valued at $1,757,000 after acquiring an additional 215,995 shares in the last quarter. Jane Street Group LLC grew its position in MiMedx Group by 133.6% in the third quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock valued at $1,806,000 after acquiring an additional 174,797 shares in the last quarter. Barclays PLC grew its position in MiMedx Group by 163.9% in the third quarter. Barclays PLC now owns 262,449 shares of the company’s stock valued at $1,550,000 after acquiring an additional 163,005 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in MiMedx Group by 6.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock valued at $8,483,000 after acquiring an additional 92,726 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Up 1.7 %

MDXG stock opened at $7.98 on Monday. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $1.17 billion, a P/E ratio of 14.51 and a beta of 1.94. The firm has a 50 day simple moving average of $8.84 and a 200-day simple moving average of $7.66.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.